Biren Saraiya, MD
Medical Oncology · New Brunswick, NJNPI 1518173665
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $3,963 of the $4,175 with a category attached, or 94.9%. Eisai Inc. accounts for 69.0% of it on its own, with 2 other manufacturers making up the rest. Reporting peaked in 2019 at $2,868 and has fallen 56.0% since, to $1,263 in 2025.
Across 7 payments — averaging $596.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eisai Inc.$3K
- Johnson & Johnson$1K
- Novartis$30
Across 279 payments — averaging $22,076 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Amgen$2.8M
- Merck$2.5M
- Regeneron$623K
- Clovis Oncology, Inc.$64K
- Pfizer$47K
- Astellas Pharma Global Development$35K
What the payments were for
- Consulting fees$3,96395%
- Travel & lodging$471%
- Food & beverage$1514%
- Education$150%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Eisai Inc. | 4 | $2,883 |
| Johnson & Johnson | 1 | $1,263 |
| Novartis | 2 | $30 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,175 in reported general payments places this provider in the 55th percentile of 112 medical oncology providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XtandiEnzalutamide | 36 | $459,085 |
| Abiraterone Acetate | 131 | $58,901 |
| OrgovyxRelugolix | 22 | $56,022 |
| Bicalutamide | 27 | $616 |
| Dexamethasone | 42 | $542 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 31 | $399 |
| Prochlorperazine Maleate | 30 | $387 |
| Prednisone | 117 | $336 |
| Oxycodone Hcl | 15 | $313 |
| Levothyroxine Sodium | 20 | $245 |
| Amlodipine Besylate | 18 | $151 |
| Ondansetron Hcl | 23 | $143 |
Paid to pharmacies, not to this prescriber.
Other medical oncology in New Brunswick
- Kristen SpencerNew Brunswick$50K
- Sarah WeissNew Brunswick$30K
- Missak HaigentzNew Brunswick$30K
- Patrick BolandNew Brunswick$29K
- Shridar GanesanNew Brunswick$27K
- Roman GroisbergNew Brunswick$22K
- Deborah ToppmeyerNew Brunswick$21K
- Morana VojnicNew Brunswick$16K
- Sanjay GoelNew Brunswick$13K
- Tina MayerNew Brunswick$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.